WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who bought shares in the company’s September 2024 IPO may be eligible to participate in and lead a class action lawsuit now pending in federal court. Cohen Milstein Sellers & Toll PLLC, a nationally recognized investor rights law firm, is actively investigating claims and encouraging shareholders with significant losses to reach out now. [Click here for information about joining the class action] If you’d like t ...

文章核心观点 - 针对购买Zenas BioPharma公司IPO相关证券的投资者发起集体诉讼，指控公司、高管、董事及承销商违反联邦证券法，因招股说明书存在重大不实陈述或遗漏，致公司股价大幅下跌 [1][5][6] 案件基本信息 - 集体诉讼代表购买或获取Zenas BioPharma公司IPO相关证券的人士发起，指控公司、部分高管和董事及IPO承销商违反联邦证券法 [1] - Zenas投资者需在2025年6月16日前申请成为集体诉讼的首席原告，可通过指定网址、电话或邮件联系获取信息 [2][3] 公司情况 - Zenas是临床阶段的全球制药公司，开发和商业化针对自身免疫性疾病患者的免疫疗法 [4] 案件指控内容 - 诉讼称IPO招股说明书存在重大事实不实陈述或遗漏，包括夸大公司用现有现金和IPO预期净收益维持运营的时间，致被告公开声明虚假误导且准备疏忽 [5] - 2024年11月12日真相披露，公司季度报告显示现有资金仅够维持12个月运营，需额外融资，公司股价从IPO的每股17美元大幅下跌 [5] - 诉讼提交当日，Zenas股价收于8.33美元，较IPO价格下跌49% [6] 律所信息 - DiCello Levitt致力于通过多种诉讼为客户争取正义，律师能力受尊重，获多项行业认可 [7][8][9] 媒体联系方式 - 联系人Amy Coker，地址为4747 Executive Drive, Suite 240, San Diego, CA 92121，电话619 - 963 - 2426，邮箱investors@dicellolevitt.com [10]

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Capti ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=144444&from=3  CLASS PERIOD: T ...

文章核心观点 - 科恩·米尔斯坦律师事务所正调查泽纳斯生物制药公司潜在证券欺诈索赔，敦促受影响投资者联系律所讨论法律权利和赔偿选项 [1] 调查相关情况 - 律所调查泽纳斯生物制药公司2024年9月首次公开募股中购买股票的投资者的潜在证券欺诈索赔 [1] - 受影响投资者可点击链接了解加入集体诉讼信息，或联系律所合伙人莫莉·J·鲍文 [2][3] 诉讼指控内容 - 美国马萨诸塞州区联邦地方法院近期提起的集体诉讼指控，泽纳斯生物制药公司及其关键利益相关者在注册声明中夸大公司财务运营期限，违反联邦证券法 [4] - 公司IPO定价为每股17美元，向公众出售超1320万股，但数周后承认只能维持12个月运营，仅为最初预计24个月的一半，导致股价暴跌 [5] - 截至2025年4月15日，公司股价收于8.72美元，较发行价下跌近49% [5] 重要截止日期 - 购买泽纳斯生物制药公司IPO股票并遭受重大损失的投资者，需在2025年6月16日前申请担任首席原告，首席原告代表所有集体成员监督诉讼，不参与也可分享潜在赔偿 [6] 律所相关介绍 - 科恩·米尔斯坦是美国领先的原告律师事务所，在证券诉讼领域经验丰富，拥有超100名律师分布在8个办公室 [7] - 该律所曾为受骗投资者挽回数十亿美元损失，获《法律500强》《法律360》等机构认可 [7] - 2024年，该律所作为联合首席律师在富国银行证券诉讼案中帮助挽回超10亿美元损失 [7]

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statemen ...

文章核心观点 Bragar Eagel & Squire, P.C.宣布对Zenas BioPharma提起集体诉讼，指控其IPO注册声明存在虚假或误导性陈述，投资者可在2025年6月16日前申请成为首席原告 [1][3] 诉讼相关 - 集体诉讼已在美国马萨诸塞州区联邦地方法院对Zenas BioPharma提起，代表在2024年9月该公司首次公开募股相关注册声明和招股说明书下购买或获得其证券的所有个人和实体 [1] - 投资者需在2025年6月16日前向法院申请成为诉讼的首席原告 [1] 指控内容 - 公司IPO注册声明包含虚假或误导性陈述，未披露公司大幅高估用现有现金和IPO预期净收益维持运营的时间 [3] - 被告公开声明在所有相关时间均存在重大虚假和误导性，且准备疏忽 [3] 联系方式 - 若购买Zenas BioPharma股票遭受损失、是长期股东、有相关信息或想了解更多索赔事宜，可通过邮箱investigations@bespc.com、电话(212) 355 - 4648或填写联系表单联系Brandon Walker或Marion Passmore，无需费用和义务 [4] 律所信息 - Bragar Eagel & Squire, P.C.是全国知名律师事务所，在纽约、加利福尼亚和南卡罗来纳设有办公室，代表个人和机构投资者参与商业、证券等复杂诉讼 [5] - 律所官网为www.bespc.com [5][7]

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development a ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...